Tourmaline Bio Inc reports results for the quarter ended in December - Earnings Summary

Tourmaline Bio

19/03/2024 21:01

* Tourmaline Bio Inc  TRML.OQ  reported a quarterly adjusted
loss
of 81 cents​​ per share for the quarter ended in December,
higher than the same quarter last year, when the company
reported EPS of $-4.40.  The mean expectation of five analysts
for the quarter was for a loss of 77 cents per share. Wall
Street expected results to range from $-1.18 to -37 cents per
share.
    * Reported revenue was zero​; analysts expected zero. 
    * Tourmaline Bio Inc's reported EPS for the quarter was a
loss
of 81 cents​.
    * The company reported a quarterly loss of $12.9 million.
    * Tourmaline Bio Inc shares had risen by 52.8% this quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 5.1%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 6 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is  "buy."

Wall Street's median 12-month price target for Tourmaline Bio
Inc is $48.50 
This summary was machine generated from LSEG data March 19 at
09:00 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.77          -0.81          Missed
 Mar. 31 2023      -3.50          -5.40          Missed